Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06425991 · ClinicalTrials.gov registry record · Phase 1
A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
A Phase 1 study of Relapsed or Refractory Multiple Myeloma, sponsored by Janssen Research & Development.
- Active
- Registry status
- Phase 1
- Development phase
- 108
- Enrollment target
- 20
- Study locations
NCT06425991: Active Phase 1 study of Relapsed or Refractory Multiple Myeloma, sponsored by Janssen Research & Development.
NCT06425991 is a Phase 1 study of Relapsed or Refractory Multiple Myeloma that is active but no longer recruiting, run by Janssen Research & Development. The registered enrollment target is 108 participants, below the 332-participant average among 10 other Relapsed or Refractory Multiple Myeloma trials with a reported enrollment target (67% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06425991, a Phase 1 study of Relapsed or Refractory Multiple Myeloma, is active but no longer recruiting, sponsored by Janssen Research & Development.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 108 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to compare the pharmacokinetics (processes by which drugs are absorbed, distributed in the body, and excreted) between teclistamab made from the current commercial manufacturing process (pre-change) and the new manufacturing process (post-change).
Primary Outcome
Cmax is defined as the maximum observed serum concentration of teclistamab (after first treatment dose).
Conditions Studied
Interventions
- DRUG Teclistamab
Study Locations (20)
Other
- Flinders Medical Centre - Bedford Park
- Box Hill Hospital - Box Hill
- Royal Prince Alfred Hospital - Camperdown
- Epworth Healthcare - Richmond
- CHRU de Lille Hopital Claude Huriez - Lille
- Hospices Civils de Lyon HCL - Lyon
- CHU Nantes - Nantes
- CHU de Bordeaux - Hospital Haut-Leveque - Pessac
- Klinikum Chemnitz gGmbH - Chemnitz
- Universitaetsklinikum Hamburg Eppendorf - Hamburg
- Universitaetsklinikum Heidelberg - Heidelberg
Arizona
- Banner MD Anderson Cancer Center - Gilbert
Colorado
- Colorado Blood Cancer Institute - Denver
Florida
- Cleveland Clinic Florida - Weston
Georgia
- Augusta University- Georgia Cancer Center - Augusta
Indiana
- St Francis Hospital & Health Centers Indiana Blood and Marrow Transplantation Franciscan Health - Indianapolis
Ohio
- Cleveland Clinic - Cleveland
Texas
- Baylor University Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2024-06-07 |
| Est. Completion | 2027-03-03 |
| Phase | Phase 1 |
What the registry record for NCT06425991 still lists
NCT06425991 is an interventional study that assigns participants to a tested intervention. The registered 108 participants enrollment target is mid-sized for trials with a published cap, below the 332-participant average among 10 other Relapsed or Refractory Multiple Myeloma trials with a reported enrollment target (67% lower).
The record links to 1 condition, with Relapsed or Refractory Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which Teclistamab is the first listed.
NCT06425991 names 20 study sites across 10 states, led by Other, Arizona, Colorado.
Frequently Asked Questions
What is clinical trial NCT06425991 about?
NCT06425991 is a clinical study titled "A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma". The purpose of this study is to compare the pharmacokinetics (processes by which drugs are absorbed, distributed in the body, and excreted) between teclistamab made from the current commercial manufacturing process (pre-change) and the new manufacturing process (post-change).
What is the current status of trial NCT06425991?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 108 participants. The study started on 2024-06-07. Estimated completion is 2027-03-03.
What conditions does trial NCT06425991 study?
This clinical trial studies the following conditions: Relapsed or Refractory Multiple Myeloma.
What interventions are being tested in trial NCT06425991?
The interventions under investigation include: Teclistamab (DRUG).
Who is sponsoring clinical trial NCT06425991?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06425991 being conducted?
This trial has 20 study locations across Arizona, Colorado, Florida, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsed or Refractory Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06425991's enrollment target sits among peer trials
108 8th of 10 higher than 3 of 10 other Relapsed or Refractory Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Relapsed or Refractory Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
-
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
RECRUITING · Phase 1
-
Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
COMPLETED · Phase 1
-
Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients
COMPLETED · Phase 1
-
A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02703207 · 108 participants · NA
Neurocognitive and Health Impact of Sleep Apnea in Elderly Veterans With Comorbid COPD
- NCT02744677 · 108 participants · NA
COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction
- NCT02781883 · 108 participants · Phase 2
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
- NCT03848663 · 108 participants · NA
Visual Remapping to Aid Reading With Field Loss
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI